[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Newest GBI Research Premium Reports on Pharmaceuticals Industry

23 Apr 2012 • by Natalie Aster

Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011. GBI Research’s analysis shows that the overall global pediatric vaccines market was valued at $14 billion in 2010. The market is expected to witness a growth at a CAGR of 11.5% between 2007 and 2017 to reach $24.3 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage and those in the later stages of development.

The vaccines market, which was once considered a low-profit segment of the top players’ portfolios, now has ability to generate high revenues and profits despite being priced at a premium. The vaccine market has captured the attention of Big Pharma who has been watching the development of this market with interest following the success story of Prevnar, the first blockbuster vaccine.

Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion. GBI Research’s analysis shows that the global anti-hypertensives market was estimated to be worth $29.9 billion in 2010, representing a Compound Annual Growth Rate (CAGR) of 5.8% between 2002 and 2010. The market is forecast to reach $33 billion by 2017 at a CAGR of 1.2%.

The primary reason for the slow down in the market growth is the patent expiries of major blockbusters in the forecast period. Drugs that are set to lose patent include Novartis’ Diovan (2012), Sanofi’s Avapro (2012), Novartis’s Exforge (2012), Takeda/AstraZeneca’s Blopress/Atacand (2012), Pfizer’s Revatio (2012), Boehringer’s Micardis (2014), United Therapeutics Remodulin (2014), Actelion’s Tracleer (2015) and Daiichi Sankyo’s Benicar (2016). These drugs together accounted for more than $20.6 billion in revenues in 2010.

Price per Report: $3.500,00 (Single User License)

More new market research reports by can be found at GBI Research.

To order the report or ask for sample pages contact [email protected]


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest